Notably, EGFR tyrosine kinase inhibitors (TKIs) against EGFR activation have been approved to treat certain kinds of cancers, such as lung and pancreatic cancers (Lee et al, 2014; Wu and Shih, 2018). This evidence concerns the gene EGFR and familial pancreatic carcinoma.